Author
Listed:
- Jaewoong Lee
(Yale Cancer Center, Yale School of Medicine)
- Mark E. Robinson
(Yale Cancer Center, Yale School of Medicine)
- Ning Ma
(City of Hope Comprehensive Cancer Center)
- Dewan Artadji
(Yale Cancer Center, Yale School of Medicine)
- Mohamed A. Ahmed
(City of Hope Comprehensive Cancer Center)
- Gang Xiao
(City of Hope Comprehensive Cancer Center)
- Teresa Sadras
(Yale Cancer Center, Yale School of Medicine)
- Gauri Deb
(City of Hope Comprehensive Cancer Center)
- Janet Winchester
(City of Hope Comprehensive Cancer Center)
- Kadriye Nehir Cosgun
(Yale Cancer Center, Yale School of Medicine)
- Huimin Geng
(University of California San Francisco)
- Lai N. Chan
(Yale Cancer Center, Yale School of Medicine)
- Kohei Kume
(Yale Cancer Center, Yale School of Medicine)
- Teemu P. Miettinen
(Massachusetts Institute of Technology
University College London)
- Ye Zhang
(Massachusetts Institute of Technology)
- Matthew A. Nix
(University of California San Francisco)
- Lars Klemm
(Yale Cancer Center, Yale School of Medicine)
- Chun Wei Chen
(City of Hope Comprehensive Cancer Center)
- Jianjun Chen
(City of Hope Comprehensive Cancer Center)
- Vishal Khairnar
(City of Hope Comprehensive Cancer Center)
- Arun P. Wiita
(University of California San Francisco)
- Andrei Thomas-Tikhonenko
(University of Pennsylvania)
- Michael Farzan
(The Scripps Research Institute)
- Jae U. Jung
(Lerner Research Institute, Cleveland Clinic)
- David M. Weinstock
(Dana Farber Cancer Institute
Harvard Medical School)
- Scott R. Manalis
(Massachusetts Institute of Technology
Massachusetts Institute of Technology)
- Michael S. Diamond
(Washington University School of Medicine in St Louis
Washington University School of Medicine in St Louis
Washington University School of Medicine in St Louis)
- Nagarajan Vaidehi
(City of Hope Comprehensive Cancer Center)
- Markus Müschen
(Yale Cancer Center, Yale School of Medicine
Yale University)
Abstract
Interferon-induced transmembrane protein 3 (IFITM3) has previously been identified as an endosomal protein that blocks viral infection1–3. Here we studied clinical cohorts of patients with B cell leukaemia and lymphoma, and identified IFITM3 as a strong predictor of poor outcome. In normal resting B cells, IFITM3 was minimally expressed and mainly localized in endosomes. However, engagement of the B cell receptor (BCR) induced both expression of IFITM3 and phosphorylation of this protein at Tyr20, which resulted in the accumulation of IFITM3 at the cell surface. In B cell leukaemia, oncogenic kinases phosphorylate IFITM3 at Tyr20, which causes constitutive localization of this protein at the plasma membrane. In a mouse model, Ifitm3−/− naive B cells developed in normal numbers; however, the formation of germinal centres and the production of antigen-specific antibodies were compromised. Oncogenes that induce the development of leukaemia and lymphoma did not transform Ifitm3−/− B cells. Conversely, the phosphomimetic IFITM3(Y20E) mutant induced oncogenic PI3K signalling and initiated the transformation of premalignant B cells. Mechanistic experiments revealed that IFITM3 functions as a PIP3 scaffold and central amplifier of PI3K signalling. The amplification of PI3K signals depends on IFITM3 using two lysine residues (Lys83 and Lys104) in its conserved intracellular loop as a scaffold for the accumulation of PIP3. In Ifitm3−/− B cells, lipid rafts were depleted of PIP3, which resulted in the defective expression of over 60 lipid-raft-associated surface receptors, and impaired BCR signalling and cellular adhesion. We conclude that the phosphorylation of IFITM3 that occurs after B cells encounter antigen induces a dynamic switch from antiviral effector functions in endosomes to a PI3K amplification loop at the cell surface. IFITM3-dependent amplification of PI3K signalling, which in part acts downstream of the BCR, is critical for the rapid expansion of B cells with high affinity to antigen. In addition, multiple oncogenes depend on IFITM3 to assemble PIP3-dependent signalling complexes and amplify PI3K signalling for malignant transformation.
Suggested Citation
Jaewoong Lee & Mark E. Robinson & Ning Ma & Dewan Artadji & Mohamed A. Ahmed & Gang Xiao & Teresa Sadras & Gauri Deb & Janet Winchester & Kadriye Nehir Cosgun & Huimin Geng & Lai N. Chan & Kohei Kume , 2020.
"IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells,"
Nature, Nature, vol. 588(7838), pages 491-497, December.
Handle:
RePEc:nat:nature:v:588:y:2020:i:7838:d:10.1038_s41586-020-2884-6
DOI: 10.1038/s41586-020-2884-6
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:588:y:2020:i:7838:d:10.1038_s41586-020-2884-6. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.